JUNIOR STRENGTH MOTRIN Drug Patent Profile
✉ Email this page to a colleague
When do Junior Strength Motrin patents expire, and what generic alternatives are available?
Junior Strength Motrin is a drug marketed by Kenvue Brands and is included in two NDAs.
The generic ingredient in JUNIOR STRENGTH MOTRIN is ibuprofen. There is one drug master file entry for this compound. Two hundred and forty-nine suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Junior Strength Motrin
A generic version of JUNIOR STRENGTH MOTRIN was approved as ibuprofen by CONTRACT PHARMACAL on October 15th, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for JUNIOR STRENGTH MOTRIN?
- What are the global sales for JUNIOR STRENGTH MOTRIN?
- What is Average Wholesale Price for JUNIOR STRENGTH MOTRIN?
Summary for JUNIOR STRENGTH MOTRIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 179 |
| Patent Applications: | 4,835 |
| DailyMed Link: | JUNIOR STRENGTH MOTRIN at DailyMed |
US Patents and Regulatory Information for JUNIOR STRENGTH MOTRIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kenvue Brands | JUNIOR STRENGTH MOTRIN | ibuprofen | TABLET, CHEWABLE;ORAL | 020601-003 | Nov 15, 1996 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Kenvue Brands | JUNIOR STRENGTH MOTRIN | ibuprofen | TABLET;ORAL | 020602-001 | Jun 10, 1996 | OTC | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for JUNIOR STRENGTH MOTRIN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases | Pedea | ibuprofen | EMEA/H/C/000549Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. | Authorised | no | no | no | 2004-07-28 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for JUNIOR STRENGTH MOTRIN
See the table below for patents covering JUNIOR STRENGTH MOTRIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 129406 | ⤷ Start Trial | |
| Australia | 6018190 | ⤷ Start Trial | |
| Australia | 646399 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for JUNIOR STRENGTH MOTRIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1781277 | PA2024501 | Lithuania | ⤷ Start Trial | PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch